Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia
The aims of this study were to investigate the frequency and prognostic relevance of CD56 expression in patients with acute myeloid leukemia (AML) and to compare the importance of CD56 expression with standard prognostic factors, such as age, leukocytosis, cytogenetic abnormalities and performance s...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2012-09, Vol.29 (3), p.2077-2082 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2082 |
|---|---|
| container_issue | 3 |
| container_start_page | 2077 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 29 |
| creator | Djunic, Irena Virijevic, Marijana Djurasinovic, Vladislava Novkovic, Aleksandra Colovic, Natasa Kraguljac-Kurtovic, Nada Vidovic, Ana Suvajdzic-Vukovic, Nada Tomin, Dragica |
| description | The aims of this study were to investigate the frequency and prognostic relevance of CD56 expression in patients with acute myeloid leukemia (AML) and to compare the importance of CD56 expression with standard prognostic factors, such as age, leukocytosis, cytogenetic abnormalities and performance status. We analyzed the data of 184 newly diagnosed patients with non-promyelocytic AML and a follow-up of 36 months. The median patient age was 58 years, with a range of 18–79. CD56+ antigen was recorded in 40 patients (21.7%). CD56 + was the most significant risk factor for OS:
P
= 0.05. The most significant factor for a poor rate of CR was age ≥ 55 years (
P
= 0.001). CD56 positivity had no significant influence on CR rate, but it was the most significant risk factor for disease-free survival (
P
= 0.005). The CD56 antigen is an independent prognostic risk factor, and its presence should be measured regularly for a better prognostic assessment of patients with AML. |
| doi_str_mv | 10.1007/s12032-011-0104-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1035107906</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1035107906</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-384935bc59db38e9db06c5e8baa1aca531dd78d146867ca4962f3c2e5838fa183</originalsourceid><addsrcrecordid>eNp1kE1LHTEUhoMo9aP9AW4k4Kab0ZxkkkmW5dragmAXFaSbITdz5ho7k1yTGar_vrlcFRG6yEngPOc94SHkGNgZMNacZ-BM8IoBlMPqyuyQA5DSVCDgdre8hWwqJhXbJ4c53zPGQXLzgexzzjTUtTwgv3-muAoxT97R7FfB997Z4JDGni4upKI2TH6FgeLjOmHOPgbqA13byWOYMv3rpztq3TwhHZ9wiL6jA85_cPT2I9nr7ZDx0_N9RG6-ff21-F5dXV_-WHy5qpxo-FQJXRshl06abik0lsqUk6iX1oJ1VgroukZ3UCutGmdro3gvHEephe4taHFEPm9z1yk-zJindvTZ4TDYgHHOLTAhgTWGqYKevkPv45xC-d2GargyRm0o2FIuxZwT9u06-dGmpwK1G_HtVnxbxLcb8a0pMyfPyfNyxO514sV0AfgWyKUVVpjerv5f6j9TjY1m</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1037269966</pqid></control><display><type>article</type><title>Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Djunic, Irena ; Virijevic, Marijana ; Djurasinovic, Vladislava ; Novkovic, Aleksandra ; Colovic, Natasa ; Kraguljac-Kurtovic, Nada ; Vidovic, Ana ; Suvajdzic-Vukovic, Nada ; Tomin, Dragica</creator><creatorcontrib>Djunic, Irena ; Virijevic, Marijana ; Djurasinovic, Vladislava ; Novkovic, Aleksandra ; Colovic, Natasa ; Kraguljac-Kurtovic, Nada ; Vidovic, Ana ; Suvajdzic-Vukovic, Nada ; Tomin, Dragica</creatorcontrib><description>The aims of this study were to investigate the frequency and prognostic relevance of CD56 expression in patients with acute myeloid leukemia (AML) and to compare the importance of CD56 expression with standard prognostic factors, such as age, leukocytosis, cytogenetic abnormalities and performance status. We analyzed the data of 184 newly diagnosed patients with non-promyelocytic AML and a follow-up of 36 months. The median patient age was 58 years, with a range of 18–79. CD56+ antigen was recorded in 40 patients (21.7%). CD56 + was the most significant risk factor for OS:
P
= 0.05. The most significant factor for a poor rate of CR was age ≥ 55 years (
P
= 0.001). CD56 positivity had no significant influence on CR rate, but it was the most significant risk factor for disease-free survival (
P
= 0.005). The CD56 antigen is an independent prognostic risk factor, and its presence should be measured regularly for a better prognostic assessment of patients with AML.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-011-0104-9</identifier><identifier>PMID: 22081445</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers, Tumor - analysis ; CD56 Antigen - biosynthesis ; Disease-Free Survival ; Female ; Hematology ; Humans ; Internal Medicine ; Kaplan-Meier Estimate ; Leukemia ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - metabolism ; Leukemia, Myeloid, Acute - mortality ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Paper ; Pathology ; Prognosis ; Proportional Hazards Models ; Young Adult</subject><ispartof>Medical oncology (Northwood, London, England), 2012-09, Vol.29 (3), p.2077-2082</ispartof><rights>Springer Science+Business Media, LLC 2011</rights><rights>Springer Science+Business Media, LLC 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-384935bc59db38e9db06c5e8baa1aca531dd78d146867ca4962f3c2e5838fa183</citedby><cites>FETCH-LOGICAL-c372t-384935bc59db38e9db06c5e8baa1aca531dd78d146867ca4962f3c2e5838fa183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-011-0104-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-011-0104-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22081445$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Djunic, Irena</creatorcontrib><creatorcontrib>Virijevic, Marijana</creatorcontrib><creatorcontrib>Djurasinovic, Vladislava</creatorcontrib><creatorcontrib>Novkovic, Aleksandra</creatorcontrib><creatorcontrib>Colovic, Natasa</creatorcontrib><creatorcontrib>Kraguljac-Kurtovic, Nada</creatorcontrib><creatorcontrib>Vidovic, Ana</creatorcontrib><creatorcontrib>Suvajdzic-Vukovic, Nada</creatorcontrib><creatorcontrib>Tomin, Dragica</creatorcontrib><title>Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>The aims of this study were to investigate the frequency and prognostic relevance of CD56 expression in patients with acute myeloid leukemia (AML) and to compare the importance of CD56 expression with standard prognostic factors, such as age, leukocytosis, cytogenetic abnormalities and performance status. We analyzed the data of 184 newly diagnosed patients with non-promyelocytic AML and a follow-up of 36 months. The median patient age was 58 years, with a range of 18–79. CD56+ antigen was recorded in 40 patients (21.7%). CD56 + was the most significant risk factor for OS:
P
= 0.05. The most significant factor for a poor rate of CR was age ≥ 55 years (
P
= 0.001). CD56 positivity had no significant influence on CR rate, but it was the most significant risk factor for disease-free survival (
P
= 0.005). The CD56 antigen is an independent prognostic risk factor, and its presence should be measured regularly for a better prognostic assessment of patients with AML.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers, Tumor - analysis</subject><subject>CD56 Antigen - biosynthesis</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - metabolism</subject><subject>Leukemia, Myeloid, Acute - mortality</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Young Adult</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kE1LHTEUhoMo9aP9AW4k4Kab0ZxkkkmW5dragmAXFaSbITdz5ho7k1yTGar_vrlcFRG6yEngPOc94SHkGNgZMNacZ-BM8IoBlMPqyuyQA5DSVCDgdre8hWwqJhXbJ4c53zPGQXLzgexzzjTUtTwgv3-muAoxT97R7FfB997Z4JDGni4upKI2TH6FgeLjOmHOPgbqA13byWOYMv3rpztq3TwhHZ9wiL6jA85_cPT2I9nr7ZDx0_N9RG6-ff21-F5dXV_-WHy5qpxo-FQJXRshl06abik0lsqUk6iX1oJ1VgroukZ3UCutGmdro3gvHEephe4taHFEPm9z1yk-zJindvTZ4TDYgHHOLTAhgTWGqYKevkPv45xC-d2GargyRm0o2FIuxZwT9u06-dGmpwK1G_HtVnxbxLcb8a0pMyfPyfNyxO514sV0AfgWyKUVVpjerv5f6j9TjY1m</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Djunic, Irena</creator><creator>Virijevic, Marijana</creator><creator>Djurasinovic, Vladislava</creator><creator>Novkovic, Aleksandra</creator><creator>Colovic, Natasa</creator><creator>Kraguljac-Kurtovic, Nada</creator><creator>Vidovic, Ana</creator><creator>Suvajdzic-Vukovic, Nada</creator><creator>Tomin, Dragica</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120901</creationdate><title>Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia</title><author>Djunic, Irena ; Virijevic, Marijana ; Djurasinovic, Vladislava ; Novkovic, Aleksandra ; Colovic, Natasa ; Kraguljac-Kurtovic, Nada ; Vidovic, Ana ; Suvajdzic-Vukovic, Nada ; Tomin, Dragica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-384935bc59db38e9db06c5e8baa1aca531dd78d146867ca4962f3c2e5838fa183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers, Tumor - analysis</topic><topic>CD56 Antigen - biosynthesis</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - metabolism</topic><topic>Leukemia, Myeloid, Acute - mortality</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Djunic, Irena</creatorcontrib><creatorcontrib>Virijevic, Marijana</creatorcontrib><creatorcontrib>Djurasinovic, Vladislava</creatorcontrib><creatorcontrib>Novkovic, Aleksandra</creatorcontrib><creatorcontrib>Colovic, Natasa</creatorcontrib><creatorcontrib>Kraguljac-Kurtovic, Nada</creatorcontrib><creatorcontrib>Vidovic, Ana</creatorcontrib><creatorcontrib>Suvajdzic-Vukovic, Nada</creatorcontrib><creatorcontrib>Tomin, Dragica</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Djunic, Irena</au><au>Virijevic, Marijana</au><au>Djurasinovic, Vladislava</au><au>Novkovic, Aleksandra</au><au>Colovic, Natasa</au><au>Kraguljac-Kurtovic, Nada</au><au>Vidovic, Ana</au><au>Suvajdzic-Vukovic, Nada</au><au>Tomin, Dragica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>29</volume><issue>3</issue><spage>2077</spage><epage>2082</epage><pages>2077-2082</pages><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>The aims of this study were to investigate the frequency and prognostic relevance of CD56 expression in patients with acute myeloid leukemia (AML) and to compare the importance of CD56 expression with standard prognostic factors, such as age, leukocytosis, cytogenetic abnormalities and performance status. We analyzed the data of 184 newly diagnosed patients with non-promyelocytic AML and a follow-up of 36 months. The median patient age was 58 years, with a range of 18–79. CD56+ antigen was recorded in 40 patients (21.7%). CD56 + was the most significant risk factor for OS:
P
= 0.05. The most significant factor for a poor rate of CR was age ≥ 55 years (
P
= 0.001). CD56 positivity had no significant influence on CR rate, but it was the most significant risk factor for disease-free survival (
P
= 0.005). The CD56 antigen is an independent prognostic risk factor, and its presence should be measured regularly for a better prognostic assessment of patients with AML.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>22081445</pmid><doi>10.1007/s12032-011-0104-9</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2012-09, Vol.29 (3), p.2077-2082 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1035107906 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - analysis CD56 Antigen - biosynthesis Disease-Free Survival Female Hematology Humans Internal Medicine Kaplan-Meier Estimate Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - metabolism Leukemia, Myeloid, Acute - mortality Male Medicine Medicine & Public Health Middle Aged Oncology Original Paper Pathology Prognosis Proportional Hazards Models Young Adult |
| title | Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T23%3A00%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20CD56%20antigen%20expression%20in%20patients%20with%20acute%20myeloid%20leukemia&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Djunic,%20Irena&rft.date=2012-09-01&rft.volume=29&rft.issue=3&rft.spage=2077&rft.epage=2082&rft.pages=2077-2082&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-011-0104-9&rft_dat=%3Cproquest_cross%3E1035107906%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1037269966&rft_id=info:pmid/22081445&rfr_iscdi=true |